CMC Biologics a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika have added Cerbios-Pharma and Oncotec Pharma Produktion to PROVEO, their strategic collaboration for providing a complete and efficient solution to the market for the process development and manufacture of antibody drug conjugates (ADCs).

Within the PROVEO collaborative partnership, CMC Biologics provides monoclonal antibody production, Cerbios performs process development and manufacture of the cytotoxic drug-linker payload, and the conjugation services of the ADC drug substance. Oncotec provides aseptic fill and lyophilization of the ADC drug product, and IDT Biologika performs analytical and quality services, supply chain and secondary packaging through to ready-to-deliver final drug product. These services will be available in early 2017 and will further complete PROVEO’s full ADC service offering.

“We are pleased to join CMC Biologics and IDT Biologika in the development and production of ADCs,” said Gabriel Haering, chief executive officer, Cerbios. “Our extensive experience in the manufacture of cytoxic drug payloads and conjugation to antibodies will be valuable to clients utilizing the ADC services provided by the PROVEO partnership. Our approved Safebridge Category 4, GMP facility in Lugano was designed to accomodate the complex processes needed for production of very potent active ingredients including cytotoxics like ADCs.”

“Cerbios brings two decades of experience working with highly potent cytotoxic compounds and will provide a valuable addition to the ADC services offered by our PROVEO partnership,” said Gustavo Mahler, chief executive officer, CMC Biologics.

“We will leverage Cerbios’ experience with cytotoxic payloads to round out the ADC services that we offer to our clients,” said Ralf Pfirmann, chief executive officer, IDT Biologika. “We are also pleased to bring our sister company, Oncotec, into the PROVEO partnership, which will further strengthen the team and provide essential drug product expertise and capacity.”